2020 Implementation Science Consortium in Cancer (ISCC)

Please note that as of 2021, this initiative has been renamed from the Implementation Science Consortium in Cancer (ISCC) to the Consortium for Cancer Implementation Science (CCIS)

Outcomes of the 2020 ISCC Meeting

The 2020 ISCC was a working meeting that focused on short-term and long-term cancer control priorities; challenges and opportunities during the COVID-19 pandemic; synergies and gaps in the implementation science space across National Cancer Institute funded initiatives; and discussion on infrastructures for cross collaboration.

Action Group Overview and Day 1 Recap Slides

 

Session Videos


Welcome and Overview of ISCC 2020

The welcome address by David Chambers began with a brief history of IS at NCI and highlighted key efforts and activities completed in the IS field since the first ISCC in 2019. He recognized the importance of a field-wide approach to making IS a reality, emphasizing the significance of ongoing mentoring and technical assistance; capacity building in community and clinical settings; and designing the next generation of studies that are impactful, rigorous, relevant, and ambitious.

Bryan Weiner gave an overview of the 2020 ISCC attendees, outlined the meeting objectives, and walked through the meeting agenda. Over the course of two days, attendees were given the opportunity to participate in two panel discussions and a town hall meeting, and dive into deeper conversation in two of the eight action groups.


Synergies, Gaps and Opportunities in Implementation Science (IS)

The Day 1 panel looked at the synergies, gaps, and opportunities for involvement in IS and cancer control through a dialogue with representatives from various federally funded initiatives that are either focused on IS and cancer control or may have a significant IS component. Some of these are NCI Cancer Moonshot-funded, and some predate the Cancer Moonshot.

Watch these 8 short videos to learn more about these different federally funded implementation science initiatives represented on the panel.


Virtual Report Out from Day 1 Action Groups

The IS action groups gave meeting attendees the opportunity to participate in deep conversations with their IS colleagues about two of eight IS priority subjects. The action groups met to brainstorm how to move the topic forward by developing “public goods” to benefit the field, identify concrete next steps, and identify volunteers to lead/co-lead/collaborate on specific actionable ideas. These meetings served as a launching pad for future cross-field collaboration.


Practitioner Perspectives: Considering COVID-19 and IS in Cancer Control

The Day 2 panel discussion brought together practitioners in cancer control to discuss how COVID-19 and the related mitigation responses have impacted cancer control efforts among communities and in clinical settings. Additionally, the panelists discussed the role that IS could play in addressing the cancer control priorities of practices in cancer care delivery organizations and addressed the unique issues that have arisen in the midst of the pandemic.


Town Hall: Setting the Stage for IS in Cancer Control in the Coming Year

Led by David Chambers, meeting participants were guided through a series of questions to receive feedback on their experience over the two-day meeting. With the help of Mentimeter, Chambers was able to collect and audibly review attendee responses to the questions. The questions covered topics including main takeaways, the IS community, and advice for the consortium moving forward.

 

Prajakta Adsul, MBBS, MPH, PhD
University of New Mexico Comprehensive Cancer Center

Sarah Bruce Bernal, MA
National Cancer Institute

Heather Brandt, PhD, CHES
St. Jude Children’s Research Hospital

David Chambers, DPhil
National Cancer Institute

Mindy Clyne, MHS, CGC
National Cancer Institute

Maria Fernandez, PhD
UT Health Science Center, Houston

Kristie Long Foley, PhD
Wake Forest School of Medicine

Simon Craddock Lee, PhD MPH
UT Southwestern Simmons Comprehensive Cancer Center

Hope Krebill, MSW, BSN, RN
University of Kansas Medical Center

Brian Mittman, PhD
Kaiser Permanente Southern California

Wynne Norton, PhD
National Cancer Institute

April Oh, PhD, MPH
National Cancer Institute

Alanna Kulchak Rahm, PhD, MS, LGC
Geisinger

Donna Shelley, MD, MPH
NYU Langone Health

Rachel Shelton, ScD, MPH
Columbia University, Mailman School of Public Health

Cynthia Vinson, PhD, MPA
National Cancer Institute

Bryan Weiner, PhD
University of Washington

Stephanie Wheeler, PhD, MPH
University of North Carolina, Chapel Hill

Last Updated
July 15, 2021